Agoracom Blog Home

Posts Tagged ‘covid 19 testing’

Datametrex $DM.ca Reports First Quarter Results

Posted by AGORACOM-JC at 8:42 AM on Wednesday, May 27th, 2020

Highlights for Q1 2020

  • The Company completed work for Democracy Labs on #disinformation in social media regarding #covid19 and #coronavirus and secured a relationship with Carnegie Mellon University IDeaS. These projects assisted in getting Nexalogy in front of the Government Agencies for the opportunity in the United States.
  • The Company continued the second phase of a multi-phase R&D program through the Department of National Defence’s Innovation for Defence Excellence and Security IDEaS program.  
  • The Company was chosen as preferred vendor partner by LOTTE Data Communication.

TORONTO, May 27, 2020 — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce its financial results for Q1, ended March 31, 2020. 

Although certain projects and various sales negotiations have been postponed due to COVID-19 outbreaks, the Company was able to expand its businesses, and recorded increase in revenue for Q1 2020 by 62%, $809,402 compared to $498,565 in the previous year. Operating costs were reduced by 31% to $1,162,723 compared to $1,692,958 in the previous year. The net results  improved significantly with a decrease by 25%, ($721,761) compared to ($904,792) in the previous year. The Adjusted EBITDA also had a significant improvement with a decrease by 177%, ($257,303) compared to ($712,256). 

“In Q1 2020, we achieved multiple key milestones and made significant strides in strengthening our AI platform and offering, reducing operating costs, increasing sales, and focusing on our core business. This resulted in a substantial improvement to the bottom line,” says Marshall Gunter, CEO of the Company.

Highlights for Q1 2020

  • The Company completed work for Democracy Labs on #disinformation in social media regarding #covid19 and #coronavirus and secured a relationship with Carnegie Mellon University IDeaS. These projects assisted in getting Nexalogy in front of the Government Agencies for the opportunity in the United States.
  • The Company continued the second phase of a multi-phase R&D program through the Department of National Defence’s Innovation for Defence Excellence and Security IDEaS program.  
  • The Company was chosen as preferred vendor partner by LOTTE Data Communication.

Financial Highlights

The following table summarizes revenue, net loss and EBITDA* and Adjusted EBITDA* for the three months ended March 31, 2020 and 2019.

 For the three months ended 
 March 31, 2020 March 31, 2019 %
 $ $  
REVENUE  809,402   498,565 62%
NET LOSS  (721,761)  (904,792)25%
EBITDA  (528,303)  (723,529)37%
EBITDA per share  (0.002)  (0.003)68%
Adjusted EBTDA  (257,303)  (712,256)177%
Adjusted EBITDA per share  (0.001)  (0.003)34%

* Note: EBITDA (non-IFRS measures) is calculated as Net Loss ($721,761) adjusted for 1. Income taxes of ($16,207), 2. Depreciation and amortization of $194,899, and 3. Interest and accretion of $14,766. Adjusted EBITDA (non-IFRS measures) is calculated as EBITFA adjusted for share based compensation of 271,000.

Non-IFRS financial measures do not have standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Specific items may only be relevant in certain periods. For reconciliation of non-IFRS financial measures please refer to the Company’s Management Discussion and Analysis for the three months ended March 31, 2020.

The financial statements, notes to the financial statements and Management’s Discussion and Analysis for the three months ended March 31, 2020 are available on the Company’s profile at SEDAR at www.sedar.com.

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com).

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Jeff Stevens- Advisor
Phone: (647) 400-8494
Email: [email protected]

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws.  All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

INTERVIEW: Datametrex $DM.ca Sells 10,000 COVID-19 Test Kits In $500,000 Deal With Global Mining Company

Posted by AGORACOM-JC at 9:16 AM on Thursday, May 21st, 2020

When US Government Agencies call you in the middle of the greatest health and economic crisis in 100 years to help them detect social media disinformation about COVID-19, it is safe to assume your Artificial Intelligence capabilities to detect fake news, disinformation campaigns and their impact is amongst the most respected in the world.

Then, when the Canadian government calls on you to help with the import and sale of COVID-19 test kits from South Korea, it is also safe to assume your trust and security clearances are at the highest levels possible.

But the real credibility payoff comes when a global mining giant, with 4,000 employees across the world, knocks on your door to buy 10,000 kits for the purposes of protecting both their employees and their families in order to get operations re-started.

You would probably also assume such a company to be a tech giant or a Silicon Valley funded startup. But Datametrex AI (DM: TSXV) is neither. Rather, it is a great Canadian small cap technology company who is giving small cap investors an opportunity to participate in the emerging world of Artificial Intelligence, as well as, the brand new world of COVID-19 testing.

When a small cap Artificial Intelligence company is successfully deploying its technology with military and conglomerates, as well as, being called upon by the Canadian federal government and global conglomerates to ask for help with the greatest pandemic in 100 years, smart small cap investors are compelled to take a closer look.

That look can begin with our latest interview of Datametrex CEO, Marshall Gunter, who discusses how the Company was able to secure its first order of 10,000 COVID-19 test kits for $500,000.

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

Datametrex $DM.ca Enters Strategic Agreement to Help Provide for Processing of COVID-19 Tests for Canadian Companies

Posted by AGORACOM-JC at 9:09 AM on Thursday, May 21st, 2020
  • Signed a Strategic Partnership and Development Agreement with Transpharm Canada Inc.
  • Under the term of the Agreement TCI will work with Datametrex on scoping out services and providing access to its 25,000 sq. ft state-of-the-art testing facility located in Toronto, ON, to provide support and testing services for COVID-19 testing kits that Datametrex has in its portfolio
  • Datametrex will be providing the COVID-19 test kits. TCI will be providing all other services including but not limited to the collection of specimens, transport of specimens, and processing test results.

TORONTO, May 21, 2020 – Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that is has signed a Strategic Partnership and Development Agreement (the “Agreement”) with Transpharm Canada Inc. (“TCI”).

Under the term of the Agreement TCI will work with Datametrex on scoping out services and providing access to its 25,000 sq. ft state-of-the-art testing facility located in Toronto, ON, to provide support and testing services for COVID-19 testing kits that Datametrex has in its portfolio. Datametrex will be providing the COVID-19 test kits. TCI will be providing all other services including but not limited to the collection of specimens, transport of specimens, and processing test results.

TCI will design, engineer, and develop a fully integrated suite of testing systems that will include in the field and lab testing protocols using TCI’s fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility. TCI lab has a current capacity to process 2,304 nucleic acid COVID-19 real-time detection kits (the “Kits”) every 24 hrs using CFX96 real-time PCR detection system machines and is scalable to over 10,000 test kits every 24 hrs.

Transpharm will develop a Point of Care Diagnostic Kit System (the “TCI System”) with clear protocols of specimen collection, specimen handling, and specimen container labeling including the patient’s full name, date of collection, and one other unique identifier such as date of birth or government issued health card number. Transpharm will also develop a procedure focused around delivery related to specimen transport media tube protocols including to ensure cap on tube is tightly sealed, shipped at 2-8°C, 26-46°F to the TCI laboratory testing facility.

Datametrex is committed to helping Canada and Canadians find a safe and secure way to get people out of lockdown and back to work. The Company first identified the need for high quality test kits back in April, since then, it has established relationships with four South Korean manufacturers of nucleic acid test kits. The Company quickly identified that both public and private corporations are not fully equipped to administer and process the test kits on their own. As a result, the Company quickly sourced a qualified lab testing company to partner with that will provide customers with a turnkey solution to administer tests efficiently, safely, and accurately. The Company believes testing is going to be key to re-opening the economy in a safe fashion, and also believes in providing Canadians with the best solution. 

“By participating in this project, Datametrex reaffirms its commitment to helping it customers, shareholders, families, and the Canadian public. This project hopes to aid in the reopening of businesses, travel, places of worship, community spaces, and social and cultural events in a safe and economic way,” said Marshall Gunter, CEO of Datametrex.

Dr. Alexander MacGregor, founder and President of TCI, stated, “Transpharm is pleased to join in the COVID-19 fight with Datametrex and provide a world class testing facility for this endeavour. This world pandemic poses an unprecedented threat to the way that most people live their daily lives. There are several obvious steps we can take to ensure that no one must choose between their health and leaving their homes, and that begins with testing. Transpharm has the people, the equipment, and world class lab space to meet the enormous demand coming and to get the job done.”

About Transpharm Canada Inc

Transpharm Canada Inc. provides pharmaceutical education, technology, and research opportunities to students through its subsidiary, Toronto Institute of Pharmaceutical Technology, North America’s premier pharmaceutical training institute. The facility is also fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility and is a full-service clinical development business that provides clinical trial services to biotechnology companies.  Additional information on TIPT is available at www.tipt.com

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com).

Additional information on Datametrex is available at www.datametrex.com

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws.  All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations, and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Datametrex $DM.ca Adds Pharmacologist Alex MacGregor to the Medical Advisory Board

Posted by AGORACOM-JC at 10:04 AM on Tuesday, May 19th, 2020
  • President and Dean of the Toronto Institute of Pharmaceutical Technology and Clinical Pharmacologist, Dr. Alexander MacGregor, Ph.D., a, has consented to join the Company’s Medical Advisory Board.
  • Company is also in discussion with Transpharm Canada Inc. the parent company of Toronto Institute of Pharmaceutical Technology to provide lab testing services using there fully compliant Health Canada licensed Good Manufacturing Practice manufacturing and testing facility located in Toronto, ON, Canada

TORONTO, May 19, 2020 — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that President and Dean of the Toronto Institute of Pharmaceutical Technology (“TIPT”) and Clinical Pharmacologist, Dr. Alexander MacGregor, Ph.D., a, has consented to join the Company’s Medical Advisory Board.

The Company is also in discussion with Transpharm Canada Inc. (“TCI”), the parent company of Toronto Institute of Pharmaceutical Technology to provide lab testing services using their fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility located in Toronto, ON, Canada. Having a mass testing partner will be a key growth driver for the Company and will be working to solidify an agreement on this prospective joint project.

Datametrex is extremely pleased to have an medical patent holder and pharmacologist with the experience and abilities of Dr. MacGregor join its Medical Advisory Board,” said Marshall Gunter, CEO of Datametrex. “Alexander will be an excellent source of advice as the Company advances a key part of covid-19 with lab capacity and his and his teams pharmacology expertise. We welcome Dr. MacGregor and look forward to his valued contribution as the newest member of our team.”

Dr. Alexander MacGregor stated, “I am very pleased to join the Company’s medical advisory board. With this unprecedented pandemic terribly affecting people worldwide and has temporarily changed the way the world operates, I am pleased to be assisting Datametrex with my teams expertise in lab testing on the front lines and assisting developing a plan to meet the enormous demand coming in COVID-19 testing and working on lowering the curve during this outbreak.”

About Dr. Alexander MacGregor

A leader in the fields of pharmaceutical technology, research, and training, Dr. MacGregor has served as the President and Dean of Faculty of the Toronto Institute of Pharmaceutical Technology (TIPT®) since 1992.

The holder of several scientific patents, Dr. MacGregor currently oversees clinical testing trials of several drugs in the areas of cholesterol lowering, diabetes, anti-infective, post-operative pain, epilepsy, and congestive heart failure.

Dr. MacGregor obtained his Ph.D. in clinical pharmacology from the University of London Postgraduate Medical School after earning B.Sc. (Honors) in Medical Biochemistry from the Cardif University in Wales. In 1997, Dr. MacGregor completed a Master-Class Certification Program in Pharmaceutical Technology from the European Continuing Education College at the University of Liverpool.

In 1990, Dr. MacGregor moved to Canada to assume the role of managing director of Transpharm International UK Ltd., a scientific enterprise specializing in clinical testing and pharmaceutical drug licensing. Throughout the decade, Dr. MacGregor functioned as a consultant to major pharmaceutical industries in Europe, Asia, and North America.

Dr. MacGregor currently divides his time between TIPT, one of North America’s leading postgraduate pharmaceutical and research organizations, and ORx Pharmaceutical Corporation, where he serves as chairman and Chief Scientific Officer. In the latter capacity, Dr. MacGregor designs and develops clinical delivery methods of therapeutic compounds.

At TIPT, Dr. MacGregor runs a highly regarded training program in pharmaceutical sciences and technology. More than 7,500 successful TIPT graduates operate in all areas of the pharmaceutical industry including quality control analysis, regulatory affairs administration, clinical quality control, and clinical data review.

An active humanitarian within the African-Canadian community, Dr. MacGregor supports such organizations as the Canadian Association of Black Lawyers (CABL) and the Association of Black Law Enforcers (ABLE). Dr. MacGregor also donates generously to charities such as the United Way and the Nelson Mandela Children’s fund.

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com).

Additional information on Datametrex is available at www.datametrex.com

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Datametrex Announces Sale of COVID-19 Test Kit to Canadian Mining Company

Posted by AGORACOM-JC at 10:27 AM on Friday, May 15th, 2020
  • Received a purchase order for COVID-19 test kits from a Canadian based mining company with over 4,000 employees in multiple jurisdictions outside of Canada
  • Under the terms of the PO, Datametrex will sell to the purchaser an initial 10,000 units of COVID-19 Detection Kits, comprising of 10,000 3 mL Universal Transport Medium (UTM®) Sterile Swabs with 16x100mm Skirted Tubes with Plastic Red Capture Caps, and 1 Real-Time PCR Detection System machine to analyze the samples
  • Total gross sales amount is approximately $500,000 CDN, excluding shipping

TORONTO, May 15, 2020 — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce it has received a purchase order for (the “PO”) COVID-19 test kits from a Canadian based mining company with over 4,000 employees in multiple jurisdictions outside of Canada.

Under the terms of the PO, Datametrex will sell to the purchaser an initial 10,000 units of COVID-19 Detection Kits, comprising of 10,000 3 mL Universal Transport Medium (UTM®) Sterile Swabs with 16x100mm Skirted Tubes with Plastic Red Capture Caps, and 1 Real-Time PCR Detection System machine to analyze the samples. The total gross sales amount is approximately $500,000 CDN, excluding shipping. Datametrex anticipates that it will have little or no upfront costs associated with the sale of these test kits. The Company has secured all testing kits, swabs, tubes and the PCR machine from the manufacturer required to fulfill the order. All of the items will be shipped directly from manufacturers to the purchaser at their operating site in Africa.

“Datametrex is honoured to be assisting this Canadian company to protect and safeguard the health and welfare of their employees, local contractors, and the local population. We are proud to be able to help Canadians and companies to reopen businesses around the world and to help people return to work safely. We sincerely wish them and all Canadian companies the best during this pandemic,” says Marshall Gunter, CEO of the Company.

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com).

Additional information on Datametrex is available at www.datametrex.com

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.